MedTrace Logo

ARON-2 Study-Multicentric International Retrospective Study

NCT05290038 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 367

Last updated 2025-04-02

No results posted yet for this study

Summary

The ARON-2 study retrospectively analyze patients treated with pembrolizumab as first-line therapy in patients platinum-unfit or as second-line therapy in patients progressed after previous platinum-based chemotherapy. The amendment has been designed to also analyze patients treated with enfortumab vedotin progressed to previous platinum-based chemotherapy and anti-PD-1/PD-L1 inhibitor.

Conditions

Sponsors & Collaborators

  • Matteo Santoni

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-17
Primary Completion
2023-12-31
Completion
2027-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05290038 on ClinicalTrials.gov